1: Feng L, Yao HP, Zhou YQ, Zhou J, Zhang R, Wang MH. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. J Exp Clin Cancer Res. 2016 Apr 22;35:70. doi: 10.1186/s13046-016-0347-6. Erratum in: J Exp Clin Cancer Res. 2016;35(1):95. 2: Li S, Lu C, Chang X, Shen Y. Constitutive overexpression of asm18 increases the production and diversity of maytansinoids in Actinosynnema pretiosum. Appl Microbiol Biotechnol. 2016 Mar;100(6):2641-9. doi: 10.1007/s00253-015-7127-7. Epub 2015 Nov 17. doi: 10.1016/j.intimp.2014.11.004. Epub 2014 Nov 15. doi: 10.2119/molmed.2012.00302. 5: Siyu-Mao, Hong-Chen, Li-Chen, Chuanxi-Wang, Wei-Jia, Xiaoming-Chen, Huangjian-Yang, Wei-Huang, Wei-Zheng. Two novel ansamitocin analogs from Actinosynnema pretiosum. Nat Prod Res. 2013;27(17):1532-6. doi: 10.1080/14786419.2012.733388. Epub 2012 Oct 15. doi: 10.1002/mrc.2876. Epub 2012 Feb 28. doi: 10.1242/dmm.006486. Epub 2011 Apr 18.
合成参考文献
参考文献:10.1007/s11094-023-03001-0 摘要:Ahani M, Salarian M, Salehi M, Jalili N, Shafiee S, Taheri A, Farahmand L. Synthesis of Succinimidyl 4-(N-maleimidomethyl)-Cyclohexane-1-Carboxylate (SMCC) as a Linker and Conjugating Trastuzumab to Maytansinoid Derivative (DM1) Through SMCC as an Antibody-Drug Conjugate. Pharm Chem J. 2023 Dec;57(9):1384–93. doi: 10.1007/s11094-023-03001-0.